SPE-IMS-MS: An automated platform for sub-sixty second surveillance of endogenous metabolites and xenobiotics in biofluids
Clinical Mass Spectrometry · 2016
DOI: 10.1016/j.clinms.2016.11.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Mass Spectrometry, 2016. Verfasst von Xing Zhang und 26 weiteren Autor:innen. Beteiligte Einrichtung: Earth and Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, United States. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIEHS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Characterization of endogenous metabolites and xenobiotics is essential to deconvoluting the genetic and environmental causes of disease. However, surveillance of chemical exposure and disease-related changes in large cohorts requires an analytical platform that offers rapid measurement, high sensitivity, efficient separation, broad dynamic range, and application to an expansive chemical space. Here, we present a novel platform for small molecule analyses that addresses these requirements by combining solid-phase extraction with ion mobility spectrometry and mass spectrometry (SPE-IMS-MS). This platform is capable of performing both targeted and global measurements of endogenous metabolites and xenobiotics in human biofluids with high reproducibility (CV 6 3%), sensitivity (LODs in the pM range in biofluids) and throughput (10-s sample-to-sample duty cycle). We report application of this platform to the analysis of human urine from patients with and without type 1 diabetes, where we observed statistically significant variations in the concentration of disaccharides and previously unreported chemical isomers. This SPE-IMS-MS platform overcomes many of the current challenges of large-scale metabolomic and exposomic analyses and offers a viable option for population and patient cohort screening in an effort to gain insights into disease processes and human environmental chemical exposure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Earth and Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, United States.
- Agilent Technologies, Santa Clara, CA, United States.
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, United States.
Förderung
- NIGMS NIH HHS
- NIEHS NIH HHS
- NIAID NIH HHS
- NIH
- National Institute of General Medical Sciences
Zitieren
APA
Zhang, X., Romm, M., Zheng, X., Zink, E. M., Kim, Y. M., Burnum-Johnson, K. E., Orton, D. J., Apffel, A., Ibrahim, Y. M., Monroe, M. E., Moore, R. J., Smith, J. N., Ma, J., Renslow, R. S., Thomas, D. G., Blackwell, A. E., Swinford, G., Sausen, J., Kurulugama, R. T., …, & Baker, E. S. (2016). SPE-IMS-MS: An automated platform for sub-sixty second surveillance of endogenous metabolites and xenobiotics in biofluids. Clinical Mass Spectrometry. https://doi.org/10.1016/j.clinms.2016.11.002
Vancouver
Zhang X, Romm M, Zheng X, Zink EM, Kim YM, Burnum-Johnson KE, et al. SPE-IMS-MS: An automated platform for sub-sixty second surveillance of endogenous metabolites and xenobiotics in biofluids. Clinical Mass Spectrometry. 2016. doi:10.1016/j.clinms.2016.11.002
BibTeX
@article{Zhang2016,
author = {Zhang, Xing and Romm, Michelle and Zheng, Xueyun and Zink, Erika M and Kim, Young-Mo and Burnum-Johnson, Kristin E and Orton, Daniel J and Apffel, Alex and Ibrahim, Yehia M and Monroe, Matthew E and Moore, Ronald J and Smith, Jordan N and Ma, Jian and Renslow, Ryan S and Thomas, Dennis G and Blackwell, Anne E and Swinford, Glenn and Sausen, John and Kurulugama, Ruwan T and Eno, Nathan and Darland, Ed and Stafford, George and Fjeldsted, John and Metz, Thomas O and Teeguarden, Justin G and Smith, Richard D and Baker, Erin S},
title = {SPE-IMS-MS: An automated platform for sub-sixty second surveillance of endogenous metabolites and xenobiotics in biofluids},
journal = {Clinical Mass Spectrometry},
year = {2016},
doi = {10.1016/j.clinms.2016.11.002}
}
EUVIMED